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Summary 
The prevalence of cardiovascular disease in rheumatoid arthritis, as well as in other 
systemic auto-immune diseases, is increased, leading to premature death due to 
cardiovascular diseases such as myocardial infarction or ischemic cerebrovascular 
accidents. (1-3). 
In cardiovascular disease traditional risk factors, such as smoking, hypertension, 
dyslipidemia and obesity, are since long known to be of major importance (4, 5). In 
rheumatoid arthritis the increase of cardiovascular disease cannot be explained by 
traditional risk factors alone. (2, 6). This leads to a proposed scheme of  development of 
cardiovascular disease as presented in figure 1.
Figure 1 proposed scheme of development of cardiovascular disease
In the current thesis primarily the influence of disease activity on the development of 
cardiovascular disease was studied. In a longitudinal registry Solomon recently found 
a 26% decrease in cardiovascular risk when average disease activity scores dropped 10 
points as scored by a clinical disease activity index (CDAI)  (7).
In this thesis we focussed on preclinical stages of atherosclerosis. Three stages 
are defined, being endothelial activation, endothelial dysfunction and premature 
atherosclerosis, finally leading to overt clinical atherosclerosis, resulting in myocardial 






Endothelial activation is the first stage of preclinical atherosclerosis and is characterized 
by influx of inflammatory cells in the vascular wall.(8) Endothelial activation is studied 
by measuring markers  like soluble vascular cellular adhesion molecule -1 (s-VCAM-1), 
and von Willebrand factor in serum.
More recently several other biomarkers for cardiovascular disease have been 
discussed in literature. Osteoprotegerin has been subject of studies because it can act 
as a decoy for TNF-related apoptosis-inducing ligand (TRAIL), which is associated with 
CVD (9, 10). Another promising biomarker is GlycA (a nuclear magnetic resonance signal, 
derived from mobile N-acetyl methyl groups) which was correlated with coronary artery 
calcification (11).
Endothelial dysfunction
Endothelial dysfunction is the second stage of preclinical atherosclerosis, characterized 
by ongoing influx of inflammatory cells, leading to “stiffening” of the vascular wall, which 
can be measured by pulse wave analysis. In pulse wave analysis the pulse wave of the 
radial artery is visualized by tonometry. In “stiff” arteries the pulse wave is augmented. 
The  increment of the pulse wave is indicative for small artery elasticity (SAE). Low 
SAE is indicative for stiff arteries. SAE in RA has been proven to be a valid method for 
identifying endothelial dysfunction in RA (12).
Intima media thickness
The last preclinical stage is characterized by the formation of atherosclerotic plaques, 
which can be quantified by measuring the size of the intima media layer of the vascular 
wall, called intima media thickness (IMT). The plaque is formed by ongoing inflammation 
of the vascular wall, leading to oxidation of low density lipoproteins, which are absorbed 
by mononuclear cells, transforming them into foam cells (13). Intima media thickness in 
our studies was measured at the site of the common carotid artery (CCA), the carotid 
bulb (CB) and the internal carotid artery (ICA). IMT was measured twice at each side and 
reported as mean of the mean scores or  mean of the maximum scores.  Increment of 
IMT in the general population has been shown to be a predictor of CVD (14, 15).  Also in 
RA increased IMT has been shown to be associated with an increase in cardiovascular 
events (16). 
Advanced glycation endproducts (AGE’s)
In chronic stages of hyperglycemia or oxidative stress (as occurs in chronic inflammation) 
advanced glycation endproducts (AGE’s) are formed due to cross linking of proteins, 
nucleic acids and lipids (17, 18). These AGE’s have been shown to be predictive of 
cardiovascular disease in diabetics and non-diabetics (19-21). 
AGE’s can be quantified in  the skin by autofluorescence (22), but can also be found in 
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atherosclerotic plaques, serum and urine. In this thesis quantification of AGE’s in the skin 
was used as this reflects oxidative stress over a longer period of time. 
Angiogenic factors
The role of angiogenic factors like vascular endothelial growth factor (VEGF) and 
angiopoietin-2 (Angpt-2) in inflammation and atherosclerosis is still a matter of debate. Both 
VEGF and Angpt-2 are important mediators of angiogenesis. VEGF is produced by several 
cells like leucocytes, endothelial cells, synovial cells and macrophages (23). Together with 
Angpt-2 it promotes vascular permeability, rendering the endothelium sensitive to pro-
inflammatory cytokines (24, 25) As angiogenesis and inflammation are closely connected 
it is still unclear which factor is most important in the process of atherosclerosis (26).
Endothelial progenitor cells (EPC’s)
EPC’s are bone marrow-derived cells that are characterized by expression of CD 34 
and CD 133 on the cell surface (27). These cells have shown to be important in vascular 
repair (28). Identification of EPC’s can be performed by FACS analysis or by culturing 
peripheral blood mononuclear cells (PBMC’s) as described by Hill et al (29). As failure 
of endothelial repair might lead to atherosclerosis, depletion or dysfunction of EPC’s 
might be indicative of premature atherosclerosis.
Results of the studies
Chapter 3 discusses a cross-sectional study in 49 RA patients compared with 50 healthy 
controls. We hypothesized that SAE is present in RA and correlates with markers of 
disease activity, disability and damage. Also, we related SAE to markers of endothelial 
activation and IMT. 
We found that SAE is decreased in RA and inversely related with age, smoking, blood 
pressure, vWF, sVCAM-1, hsCRP and IMT. In multivariate linear regression analysis SAE 
was independently related to the presence of RA and the HAQ score. 
Surprisingly, IMT was not increased in RA as compared to healthy controls.  Possibly, 
this is due to the fact that disease activity in our cohort of RA patients was low. This 
finding was confirmed by a recent larger study which also found no difference in IMT 
between RA patients with moderate disease activity and HC (30) Another possible 
explanation for the fact that we did not find a difference in IMT between patients and 
controls despite the presence of a difference in endothelial dysfunction might be that 
endothelial dysfunction is present prior to thickening of the intima media. 
Chapter 4 discusses a cross-sectional study in 49 RA patients with established disease 
and 49 healthy controls (HC). We hypothesized that AGE’s are elevated in RA patients 




dysfunction and IMT. We also expected to find a correlation between Sharp vd Heijde 
scores and the amount of AGE accumulation, since both are markers of a prolonged 
inflammatory state.
Disease activity was relatively low in our group of RA patients, as indicated by DAS-28 
scores: median 2.9, range 0.8-6.9. We found that AGE’s were increased in RA compared 
to HC (median 2.4 a.u., range 1.6- 4.2, and median 2.2 a.u., range 1.3-3.8, respectively, 
P=0.03). Also endothelial cell activation was present in RA: sVCAM-1 491 ng/ml (range 
274-909) vs. 354 ng/ml (range 224-691) in HC, P<0.0001, and vWF 154 ng/ml (range 49-
603) vs. 97 ng/ml (range 22-298) in HC, P =0.002. SAE was significantly decreased in 
RA, 3.9 ml/mmHg (range 1.4-12.2) compared to 6.1 in HC (range 1.7-12.9). IMT was not 
different between RA and HC. Moreover, when the groups of RA patients and HC were 
combined, AGE’s correlated with vWF, sVCAM-1 and IMT, and were inversely related with 
SAE. This indicates that AGE’s may be used as a marker for early atherosclerosis in RA. 
In contrast to our study, others did find an increase of IMT in RA (31-33). This might be 
explained by the fact that disease activity in our cohort was low. 
Unexpectedly, AGE’s did not correlate with Sharp-vd Heijde score (SvdH score), 
indicating that damage in joints is not correlated with atherosclerosis in vessels. Another 
study found a tendency to a correlation of SvdH score with AGE accumulation (34). 
In Chapter 5 a cohort of 176 RA patients  was followed for 12.5years. The angiogenic 
factors Angpt-2 and VEGF as well as the endothelial activation marker sVCAM-1 were 
measured at entry and after 2 years. Inflammation markers and disease activity were 
measured regularly as well as the Sharp-vd Heijde score. Prevalence of CVD was 
retrieved from medical records. 
In early RA, VEGF and Angpt-2 were increased compared with healthy controls, and 
correlated with markers of inflammation. Angpt-2 levels significantly correlated with 
measures of disease activity. Nearly 18% of these 176 RA patients developed CVD after 
an average of 12.5years of disease, and these patients had a significantly higher level of 
Angpt-2 at the onset of RA compared to those who did not develop CVD.
We concluded that increased levels of Angpt-2 might be predictive for developing 
CVD later in the course of the disease.
In chapter 6 endothelial progenitor cells (EPC’s) were measured in an RA cohort, 
consisting of 27 RA patients with early disease and in 15 healthy controls (HC). EPC’s are 
presumed to play an important role in endothelial repair (28). Shortage of EPC’s might 
be related to early atherosclerosis. 
In our cohort EPC’s were measured by FACS analysis, identifying CD34/CD133 positive 
cells presumed to be EPC’s, and by counting colony forming unit’s (CFU’s). Results were 
related to markers of endothelial cell activation and endothelial dysfunction as well as 
to disease activity.
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Numbers of EPC’s as detected by FACS analysis and by CFU counts as well as SAE were 
decreased in these 27 RA patients compared to 15 HC (p=0.02, p<0.0001, and p=0.02, 
respectively), whereas the endothelial activation markers von Willebrand factor (vWF), 
soluble vascular cell adhesion molecule (sVCAM)-1 and vascular endothelial growth 
factor (VEGF) were increased (p=0.0002, p=0.05 and p=0.04, respectively). Numbers of 
EPCs and CFUs were correlated to SAE and inversely correlated to the DAS-28 score. 
EPC numbers were inversely correlated to angiopoietin-2 (ANGPt-2) and sVCAM-1 levels. 
Reason for a lower EPC count in peripheral blood in RA might be that EPC’s migrate to 
the inflamed joint, as was shown by Ruger et al. (35).
In view of the inverse relation with sVCAM-1 and disease activity, decrease in EPC’s 
might be used as an early marker of atherosclerosis.
In chapter 7 we described a longitudinal study in which 58 early RA patients were 
screened for premature markers of atherosclerosis at the onset of the study and after 
one year. We found that at entry endothelial cell dysfunction was present in RA as 
compared with HC (n=15), (SAE   3.4 ml/mmHg100, range 1.2-9.0 in RA vs. 6.1, range 
5.0-15.3 in HC, P<0.0001). Also, the endothelial cell activation markers s-VCAM-1 and 
vWF were increased (391 ng/ml (256-680) in RA vs. 341 ng/ml (223-691) in HC, P=0.0015, 
and 120 ng/ml in RA (26.5-342) vs. 99 ng/ml (22-298) in HC, P=0.02, respectively). SAE 
correlated inversely with DAS-28 (r=-0.31, P=0.016). AGE’s were increased in RA ( 2.55 
a.u. (1.29-4.65)) in comparison to HC ( 2.12 a.u. (1.32-3.82)), P=0.003. In multivariate 
analysis with SAE as independent variable, at entry SAE proved to be independently 
and inversely related to the presence of RA, age and systolic blood pressure. After one 
year SAE had significantly improved in RA from 3.4 ml/mmHg100 (1.2-9.0) to 3.8 ml/
mmHg100 (1.5-10.3), P=0.03. Patients who reached remission (DAS-28< 2.6) showed 
a significant improvement in SAE (from 3.2 (1.2-9.0) to 3.9 (1.5-10.3), P=0.02) whereas 
patients who did not reach remission did not show improvement in SAE (4.0 (1.3-8.0) to 
3.8 (1.5-8.4), P=0.6).
It is remarkable that levels of sVCAM-1 in this early RA cohort (391 ng/ml (256-680) 
were considerably lower than s-VCAM-1 levels measured in the established RA cohort 
described in chapter 3 (491 ng/ml (range 274-909), despite the fact that disease activity 
was considerably lower in the established RA cohort (DAS-28 2.9, range 0.75-6.9) 
compared to the early RA cohort described in this chapter (DAS-28 4.7, range 2.1-7.8). 
This might indicate that prolonged disease activity may lead to irreversible increase in 
s-VCAM levels despite lowering disease activity.
The most important finding of this study is that reducing disease activity towards 
remission improves SAE but not to normal values. This finding contrasts with a better 
improvement in SAE in studies with anti-TNF blocking agents in established RA cohorts 
(36, 37). In our cohort most patients were treated with methotrexate and sulfasalazine, 




Arts et al. recently found in a prospective cohort study that not disease duration but 
disease activity was related to cardiovascular disease (39).
We concluded that, apparently, reducing disease activity is not enough to restore 
endothelial dysfunction and that treatment of traditional risk factors for CVD is probably 
important as well.
Finally, in chapter 8 a longitudinal pilot study is described on 14 long standing RA 
patients receiving rituximab as biological DMARD (bDMARD) therapy. We hypothesized 
that  endothelial cell activation improves following treatment with rituximab. Markers 
for premature atherosclerosis were measured at study onset and 4 months after starting 
rituximab treatment. We found that, at entry, sVCAM was increased in these 14 RA 
patients (median 542 ng/ml, range 344-1224) compared to 14 HC (327 ng/ml, range 216-
539), P<0.0005. SAE was decreased in the RA patients (3.8 ml/mmHg100, 1.9-7.6) vs. the 
HC (5.2 ml/mmHg100, 2.0-11.2), P=0.024. There was no difference in IMT between the RA 
patients (0.70 mm, 0.52-1.27) and the HC (0.72, 0.61-1.33), P=0.77. After four months, DAS-
28 declined from 4.7 (3.3-7.2) to 3.7 (2.6-6.5), P=0.01, and sVCAM decreased from 542 ng/
ml (344-1224) to 392 ng/ml (243-1013), P=0.027. SAE increased from 3.8 ml/mmHg100 
(1.9-7.6) to 5.0 ml/mmHg100 (2.2-11.3). This increase did not reach significance (P=0.66).
This study contrasts with two studies on the effect of treatment with rituximab on 
premature atherosclerosis that showed improvement of endothelial dysfunction (40, 41), 
whereas we did not find improvement of endothelial dysfunction. Possible explanation 
for this discrepancy is that in both of these studies there was a better response to 
treatment, which was underlined by a better decrease in DAS-28 scores. In our study for 
example, none of the patients reached remission ( DAS-28< 2.6).
Improvement of endothelial cell activation was present  in our study, in agreement 
with studies in which patients were treated with conventional DMARD’s (42, 43). In these 
studies decrease in sVCAM-1 was observed after a relatively short period of  time and 
treatment frequently included relatively large amounts of corticosteroids. Also, disease 
activity at baseline was much higher in the afore mentioned studies with rituximab (40, 
41) (DAS-28 being median 6.7 and 6.8 respectively), whereas DAS-28 at baseline in our 
study was 4.7 (range 4.3-7.2).  High disease activity might have a high impact on SAE, 
which might be improved by treatment with rituximab.
We speculate that the improvement of endothelial cell activation in the absence of 
improvement of SAE might indicate that damage to the vessels is irreversible.
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General conclusions
Since RA has been shown to be a risk factor for development of CVD it has become 
important to find tools for identifying patients at risk for these CVD.  In this thesis we 
found that reduction of disease activity partially reduced endothelial dysfunction. 
Reduction of disease activity is one of the items in the EULAR recommendations for 
cardiovascular risk management in RA (44).  Also we found that patients with increased 
levels of Angpt-2 at the onset of the disease are more prone to developing CVD after 
12.5yrs. Moreover, we found that the presence of RA is independently associated with 
endothelial dysfunction early in the course of the disease. 
Finally, we found that EPC’s are decreased in early RA, and that numbers of  EPC’s are 
inversely related to levels of sVCAM-1 and correlate with SAE. As such, decrease in EPC’s 
might function as an early marker for atherosclerosis in RA.
Future perspectives
It is clear that cardiovascular disease is increased in RA. Several markers for identifying 
premature atherosclerosis have been identified.  However, an individual risk score with 
a high level of prediction for cardiovascular events is needed for an optimal individual 
approach to preventive treatment. 
I want to address three future perspectives for research in this field.
1.  Further investigation of specific effects of novel bDMARD’s on CVD in RA. 
Recently,  Zhang et al found that novel users of abatacept and tocilizumab have a 
lower risk for myocardial infarction and the necessity of a  myocardial revascularization 
procedure than novel anti-TNF users (45). As anti-TNF has been shown to have positive 
effects on premature markers of atherosclerosis (36, 37, 46) still more research is needed 
to find the best DMARD strategy that gives the best protection for CVD in RA.
2. Effects of DMARD’s on lipid metabolism and function
Serum albumin A (SAA) is present in active inflammation and has been shown to have a 
deleterious effect on the anti-atherogenic capacity of HDL (47). 
Also MTX and adalimumab have been shown to have a positive effect on the 
cholesterol loading capacity and cholesterol efflux capacity of HDL in RA, thus leading to 
decrease of foam cell formation (48). On the other hand, in a large cohort no differences 
were seen in lipid profiles between RA patients and non-RA patients (49). This indicates 
that more research has to be done to further investigate the complex interaction of 




3. Role of different inflammatory-cell subtypes in atherosclerosis in RA. 
B- cells can have pro-inflammatory qualities via T-cell stimulation or antigen presentation, 
but certain B-cell subtypes, like the B10 subtype, have negative inflammatory properties 
as was recently decribed by Kalampokis et al. (50). Also, the balance in pro-inflammatory 
B-cells and anti-inflammatory B-cells is important, as was described by van der Geest et 
al. (51). How this balance can have influence on atherosclerosis can be a point of further 
investigation. Recently, CD4+CD56+CD57+ T cells and CD14 highCD16+ monocytes 
proved to be independently related to coronary artery calcification scores (52). Whether 
these cells can be influenced by therapy and what effect this will have on atherosclerosis 
might be of interest in future research.
It is hoped that with a better insight into the individual risk profile of a patients with 
RA for atherosclerosis and a better insight into the specific anti-atherogenic effects of 
biological and conventional DMARDs the increased incidence of atherosclerosis in RA 
can be ameliorated.
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